3 results
Approved WMORecruiting
To determine the maximum tolerated dose (MTD), dose limiting toxicities (DLT), and optimal dose of docetaxel that can safely be administered to patients with cancer in a weekly schedule. amendment 1The objective of the first amendment is to…
Approved WMOWill not start
This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 in subjects 18 years and older with RR DLBCL, including those with MYC Alterations.
Approved WMOPending
Primary Objective: To evaluate potential changes in body composition and REE after NMES therapy at home for 12 weeks.We hypothesize that NMES therapy would result in hypertrophy of gluteal and hamstring muscles, and an increase in LL-LBM, total LBM…